Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Terminated 3Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Diarrhea 3Prostatic Neoplasms 2Neoplasms 2Breast Neoplasms 2Vipoma 1Somatostatinoma 1Serotonin Syndrome 1Recurrence 1Rectal Neoplasms 1Pheochromocytoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphocele 1Intestinal Obstruction 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastro-enteropancreatic neuroendocrine tumor 1Gastrinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1Adenoma 1Acromegaly 1

Interventions

Octreotide 3Irinotecan 2cabazitaxel 1XRP6258 1Theophylline 1Surveys and Questionnaires 1Sugars 1Prednisone 1PHY 906 1Leucovorin 1Lapatinib 1Fluorouracil 1Erlotinib Hydrochloride 1Endoscopy 1Drugs, Investigational 1Capecitabine 1Calcium Aluminosilicate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Diarrhea × Octreotide × Clear all
NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Novartis

Phase 2 Terminated
62 enrolled 25 charts
Breast

Breast Neoplasms, Diarrhea, Neoplasms

NCT01469338 2014-11-24

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

University of Southern California

Phase 2 Terminated
9 enrolled
Genitourinary

Diarrhea, Prostatic Neoplasms

NCT00006269 2012-05-25

Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer

Novartis

Phase 3 Terminated
89 enrolled
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡